Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN002 in moderate to severe atopic dermatitis
NCT03531957Phase 2Completed
- Sponsor
- Asana BioSciences, LLC
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of gusacitinib in atopic dermatitis (AD) (4 arms), sponsored by Asana BioSciences, LLC. Primary endpoint: Eczema Area and Severity Index at 12 weeks. Started Jul 2018; status: completed.
02
Drugs
gusacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03531957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531957.